Study Demonstrating Globus Medical’s Expandable Technology Improves Lordosis and Reduces Subsidence Awarded Best Paper at SMISS

AUDUBON, Pa., Oct. 04, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today that a recent clinical study evaluating static versus expandable lateral lumbar interbody fusion devices was awarded best paper at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum held last month.

The study, led by Dr. Richard Frisch, an orthopedic surgeon at Southeastern Spine Institute, compared clinical and radiographic outcomes of sixty-four patients who underwent minimally invasive lateral lumber interbody fusion (LLIF) for symptomatic degenerative disc disease. At one year postoperative follow up, patients treated with Globus Medical’s expandable technology experienced significantly greater segmental lordosis and a significantly lower subsidence rate than those in the static group, based on radiographic evidence.  Both the expandable and static spacer groups reported similar improvements in back pain scores with no significant differences in clinical outcomes.

“Subsidence of interbody spacers is a clinical concern due to loss of disc height and foraminal height, and the recurrence of symptoms that may result in revision surgery,” said Dr. Frisch. “The preliminary results of this study suggest that expandable lateral interbody spacers offer important clinical advantages by increasing and maintaining segmental lordosis while potentially decreasing the risk of endplate damage and subsidence.”

Andrew Iott, Senior Vice President of Global Product Development, commented, “Globus Medical would like to congratulate Dr. Frisch on receiving this best paper award at SMISS. We are proud to have sponsored this important research demonstrating the benefits of expandable interbody spacers. As the market leader in expandable interbody technologies, Globus is committed to developing next generation implants that provide innovative solutions to maximize lordosis and help address sagittal imbalance.”

To access the study and learn more about Globus Medical’s portfolio of lateral expandable interbody spacers, visit  www.GlobusMedical.com/LLIF

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email:  investors@globusmedical.com
www.globusmedical.com